Multiple Myeloma

A screening of the differentially expressed genes based on the Gene Expression Omnibus database and further gene enrichment analysis indicates that the tyrosine kinase-binding protein TYROBP is a potential prognostic marker for multiple myeloma. Multiple myeloma is a refractory hematological cancer characterized by the malignant proliferation of plasma cells. The tyrosine kinase-binding protein TYROBP mediates...

Double-hit newly diagnosed multiple myeloma patients with minimal residual disease positivity have a poor prognosis compared to patients with minimal residual disease negativity, according to the results of a recent cohort study. Autologous stem cell transplantation (ASCT) is one of the novel therapeutic approaches that are beneficial for newly diagnosed multiple myeloma (NDMM) patients. The...

A random forest radiomics model achieved satisfactory diagnostic performance, and models based on joint CET1 and T2-weighted imaging demonstrated better performance than single-sequence models in differentiating spinal multiple myeloma from metastases.  Spinal metastases and spinal multiple myeloma have similar radiographic characteristics, making accurate differentiation a necessity for precision therapy.  This retrospective study established and assessed...

A new cohort study reports that soluble B-cell maturation antigen is present in the lacrimal fluid of multiple myeloma patients, with evidence of pinocytosis as the underlying mechanism contributing to the development of keratopathy in these patients. Belantamab is an anti-B-cell maturation antigen (anti-BCMA) antibody–drug conjugate approved for the pharmacological treatment of refractory multiple myeloma....

A retrospective analysis finds high-risk fluorescent in situ hybridization markers useful for stratifying real-world survival outcomes in newly diagnosed multiple myeloma patients. Interphase fluorescent in situ hybridization (iFISH) remains the standard of care for assessing prognosis in patients with newly diagnosed multiple myeloma (NDMM). There is, however, limited data regarding iFISH-based real-world survival outcomes. In...

The prognostic value of circulating plasma cells in patients with newly diagnosed multiple myeloma was examined in a recent study.  Multiple myeloma prognosis can be affected by the presence of circulating plasma cells. Higher levels of circulating plasma cells are linked to poorer prognosis. Integrating data on circulating plasma cells could refine existing prognostic models...

A recent study provides clarity on age-, gender-, and race-associated disparities in multiple myeloma incidence. The core finding is that differences largely stem from a preceding condition more common in specific groups. Multiple myeloma often develops following a premalignant, asymptomatic condition called monoclonal gammopathy of undetermined significance.  Multiple myeloma shows varying incidence rates among different...

Elranatamab demonstrated substantial and enduring responses with a favorable safety profile in patients with relapsed or refractory multiple myeloma in a phase 3 trial. Transitioning to a biweekly dosing regimen could improve safety outcomes in the long term while still ensuring the maintenance of therapeutic effectiveness. Elranatamab is a humanized bispecific antibody that targets both...

A recent study found that higher side-effect bother was related to worse health-related quality of life in multiple myeloma patients. The study also found patient–physician discordance in reporting of side effects. Multiple myeloma (MM) is the second most prevalent hematological malignancy in the United States. Evidence shows that physicians focus on survival outcomes when making...